Acalabrutinib ± obinutuzumab demonstrates durable disease control and tolerability in treatment-naïve CLL
In this MEDtalk Talha Munir, MD, Consultant Haematologist, St James’s Hospital, Leeds, UK, presents the five-years updated analysis of the phase III ELRVATE-TN trial. In this trial, treatment-naïve patients with CLL are treated with acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil. As indicated, the study demonstrates durable disease control and tolerability.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
